P255 - ECE_1844 - Efficacy and safety of setmelanotide in acquired hypothalamic obesity: Results from a double-blind, multicentre, placebo-controlled, randomised phase 3 trial
In the largest randomised, placebo-controlled trial in aHO to date, setmelanotide demonstrated significant effects over placebo in the primary and key secondary efficacy endpoints at 52 weeks, with no new safety signals.